These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 30846448)
1. Towards precision medicine: CCL2, another brick in the wall? Charpidou A; Kotteas E; Gaga M Eur Respir J; 2019 Mar; 53(3):. PubMed ID: 30846448 [No Abstract] [Full Text] [Related]
2. [A case report of anlotinib treatment of an advanced lung squamous cell cancer patients without driver gene mutations]. Liu YH; Zhang YW; Li JS; Dai XM Zhonghua Zhong Liu Za Zhi; 2019 Jun; 41(6):447-448. PubMed ID: 31216831 [No Abstract] [Full Text] [Related]
3. Long-Term Survival of a Patient With Non-Small-Cell Lung Cancer Harboring a V600E Mutation in the BRAF Oncogene. Myall NJ; Neal JW; Cho-Phan CD; Zhou LY; Stehr H; Zhou L; Diehn M; Wakelee HA Clin Lung Cancer; 2016 Mar; 17(2):e17-21. PubMed ID: 26776917 [No Abstract] [Full Text] [Related]
4. CC ligand 2 levels are increased in LPS-stimulated peripheral monocytes of patients with non-small cell lung cancer. Miotto D; Boschetto P; Bononi I; Milani G; Legorini C; Cavallesco G; Lo Cascio N; Zeni E; Fabbri LM; Mapp CE Respir Med; 2007 Aug; 101(8):1738-43. PubMed ID: 17433654 [TBL] [Abstract][Full Text] [Related]
5. Implementation of precision medicine in clinical trials in thoracic oncology: Which are the hurdles? Scagliotti GV Cancer; 2017 Dec; 123(24):4764-4766. PubMed ID: 29125618 [No Abstract] [Full Text] [Related]
6. Personalized medicine for non-small-cell lung cancer. Kucherlapati R Oncology (Williston Park); 2010 Apr; 24(5):399-400. PubMed ID: 20480736 [No Abstract] [Full Text] [Related]
7. Genetic polymorphism rs3760396 of the chemokine (C-C motif) ligand 2 gene (CCL2) associated with the susceptibility of lung cancer in a pathological subtype-specific manner in Han-ancestry Chinese: a case control study. Li X; Lin F; Zhou H BMC Cancer; 2016 May; 16():298. PubMed ID: 27145753 [TBL] [Abstract][Full Text] [Related]
8. Challenges and Strategies in Precision Medicine for Non-Small-Cell Lung Cancer. Sacco JJ; Al-Akhrass H; Wilson CM Curr Pharm Des; 2016; 22(28):4374-85. PubMed ID: 27262325 [TBL] [Abstract][Full Text] [Related]
9. IL-6 Mediates Macrophage Infiltration after Irradiation via Up-regulation of CCL2/CCL5 in Non-small Cell Lung Cancer. Wang X; Yang X; Tsai Y; Yang L; Chuang KH; Keng PC; Lee SO; Chen Y Radiat Res; 2017 Jan; 187(1):50-59. PubMed ID: 28054838 [TBL] [Abstract][Full Text] [Related]
10. Cytological reporting on lung FNA and small biopsy specimens in the era of personalized medicine. Mino-Kenudson M Cancer Cytopathol; 2017 Mar; 125(3):155-160. PubMed ID: 28297173 [No Abstract] [Full Text] [Related]
11. Redefining the Value Proposition of Precision Oncology: Can We Integrate Genomic Testing Without Overselling It? West HJ JAMA Oncol; 2018 Oct; 4(10):1423-1424. PubMed ID: 30128551 [No Abstract] [Full Text] [Related]
12. Tumor Mutation Burden: Leading Immunotherapy to the Era of Precision Medicine? Steuer CE; Ramalingam SS J Clin Oncol; 2018 Mar; 36(7):631-632. PubMed ID: 29337637 [No Abstract] [Full Text] [Related]
13. Posttreatment Surveillance Challenges in the Era of Precision Medicine. Stirling RG J Thorac Oncol; 2021 Oct; 16(10):e77-e78. PubMed ID: 34561038 [No Abstract] [Full Text] [Related]
14. [Application strategies of the third-generation EGFR-TKI in the context of precision medicine]. Zhao J; Zhang SJ; Zhou CC Zhonghua Zhong Liu Za Zhi; 2017 Feb; 39(2):86-89. PubMed ID: 28219200 [TBL] [Abstract][Full Text] [Related]
15. The role of cytology in molecular testing and personalized medicine in lung cancer: A clinical perspective. Young K; da Cunha Santos G; Card P; Leighl N Cancer Cytopathol; 2019 Feb; 127(2):72-78. PubMed ID: 30512242 [No Abstract] [Full Text] [Related]
16. [Improving the internal medical care to set up a leading model for precision medicine development in lung cancer]. Han BH Zhonghua Zhong Liu Za Zhi; 2017 Feb; 39(2):81-85. PubMed ID: 28219199 [TBL] [Abstract][Full Text] [Related]
17. [The current situation of individualized chemotherapy for advanced non-small cell lung cancer]. Yang W; Song Y Zhonghua Jie He He Hu Xi Za Zhi; 2015 Jul; 38(7):532-4. PubMed ID: 26703022 [No Abstract] [Full Text] [Related]
18. Routine Use of Intensity-Modulated Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer Is Neither Choosing Wisely Nor Personalized Medicine. Ball D; Mac Manus M; Siva S; Plumridge N; Bressel M; Kron T J Clin Oncol; 2017 May; 35(13):1492-1493. PubMed ID: 28068176 [No Abstract] [Full Text] [Related]